165 related articles for article (PubMed ID: 36814403)
1. Comparison of clinical outcomes between transplant and nontransplant therapies in myelofibrosis following failure of first-line JAK-inhibitor.
England JT; Atenafu EG; Kennedy JA; Goraya B; Cheung V; Nye T; Gauthier K; Davidson MB; Bankar A; Sibai H; Maze D; Viswabandya A; Gupta V
Am J Hematol; 2023 May; 98(5):E127-E129. PubMed ID: 36814403
[No Abstract] [Full Text] [Related]
2. Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort.
England JT; McNamara CJ; Kennedy JA; Capo-Chichi JM; Huang J; Arruda A; Nye T; Cheung V; Claudio JO; Maze D; Sibai H; Tierens A; Tsui H; Bankar A; Xu W; Stockley T; Gupta V
Leukemia; 2022 Jun; 36(6):1689-1692. PubMed ID: 35347238
[No Abstract] [Full Text] [Related]
3. Novel treatments for myelofibrosis: beyond JAK inhibitors.
Tremblay D; Mesa R
Int J Hematol; 2022 May; 115(5):645-658. PubMed ID: 35182376
[TBL] [Abstract][Full Text] [Related]
4. New Treatments for Myelofibrosis.
Tremblay D; Mesa R
Curr Treat Options Oncol; 2023 Feb; 24(2):61-75. PubMed ID: 36640223
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
Harrison C; Verstovsek S; McMullin MF; Mesa R
Br J Haematol; 2012 May; 157(4):426-37. PubMed ID: 22463737
[TBL] [Abstract][Full Text] [Related]
6. Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations.
Mascarenhas J; Mesa R
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):714-718. PubMed ID: 37357030
[TBL] [Abstract][Full Text] [Related]
7. FDA approves fourth JAK inhibitor for myelofibrosis.
Mullard A
Nat Rev Drug Discov; 2023 Nov; 22(11):862. PubMed ID: 37803081
[No Abstract] [Full Text] [Related]
8. Balancing efficacy and safety of JAK inhibitors in myelofibrosis.
Passamonti F
Leuk Res; 2014 Mar; 38(3):290-1. PubMed ID: 24444869
[No Abstract] [Full Text] [Related]
9. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
Del Rosario M; Tsai H; Dasanu CA
J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
[TBL] [Abstract][Full Text] [Related]
10. Iron chelation for myelofibrosis-related anaemia during treatment with a Janus kinase inhibitor.
Ross DM
Br J Haematol; 2022 Apr; 197(2):135-136. PubMed ID: 35147212
[No Abstract] [Full Text] [Related]
11. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
12. Janus activated kinase inhibition in myelofibrosis.
Malhotra H
Indian J Cancer; 2012; 49(3):260-5. PubMed ID: 23238141
[TBL] [Abstract][Full Text] [Related]
13. Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.
Kosiorek HE; Scherber RM; Geyer HL; Verstovsek S; Langlais BT; Mazza GL; Gotlib J; Gupta V; Padrnos LJ; Palmer JM; Fleischman A; Mesa RA; Dueck AC
Br J Haematol; 2022 Sep; 198(6):1065-1068. PubMed ID: 35751150
[No Abstract] [Full Text] [Related]
14. Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis.
Menghrajani K; Boonstra PS; Mercer JA; Perkins C; Gowin KL; Weber AA; Mesa R; Gotlib JR; Wang L; Singer JW; Talpaz M
Leuk Lymphoma; 2019 Apr; 60(4):1036-1042. PubMed ID: 30234400
[TBL] [Abstract][Full Text] [Related]
15. New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors.
Gangat N; Tefferi A
Am J Hematol; 2024 May; 99(5):978-981. PubMed ID: 38332640
[TBL] [Abstract][Full Text] [Related]
16. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
[TBL] [Abstract][Full Text] [Related]
17. Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis.
Ipek Y; Kilic B; Gunay UB; Eskazan AE
Expert Opin Investig Drugs; 2023; 32(10):931-940. PubMed ID: 37811861
[TBL] [Abstract][Full Text] [Related]
18. Myelofibrosis: to transplant or not to transplant?
Devlin R; Gupta V
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):543-551. PubMed ID: 27913527
[TBL] [Abstract][Full Text] [Related]
19. Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?
Viswabandya A; Devlin R; Gupta V
Curr Hematol Malig Rep; 2016 Feb; 11(1):6-11. PubMed ID: 26659587
[TBL] [Abstract][Full Text] [Related]
20. How many JAK inhibitors in myelofibrosis?
Ferreira BV; Harrison C
Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
